UCL also report creatinine rises on #ribociclib on poster 58. Much like @hflint.bsky.social's poster for #abemaciclib last year. I was confused by a recent message 🗞️ about this which used the global yellow card data...
@shinyblackshoe.bsky.social
@shinyblackshoe.bsky.socialUCL also report creatinine rises on #ribociclib on poster 58. Much like @hflint.bsky.social's poster for #abemaciclib last year. I was confused by a recent message 🗞️ about this which used the global yellow card data...
@medchemexpress.bsky.socialThe FDA approved #imlunestrant + #abemaciclib for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer following progression on ≥1 line of endocrine therapy.
In the phase 3 EMBER-3 trial:
🔹Median PFS: 11.1 vs 5.5 months
🔹HR for progression/death: 0.53
🔹ORR: 35% vs 15%
@pharmaphorum.bsky.social#EliLilly's oral selective oestrogen receptor degrader (#SERD) #imlunestrant (Inluriyo), has received a second #FDA approval, this time in #combination with #CDK4/6 inhibitor #abemaciclib (Verzenio), another Lilly drug.
@dfcibreastonc.bsky.socialWe are leading a new study to evaluate the safety and effectivenessof a new drug known as #Avutometinib (#Avmapki®) in combinationwith the drugs #abemaciclib (Verzenio®) and #fulvestrant(Faslodex®) in metastatic hormone receptor-positive and HER2-negative (HR+/HER2-) #BreastCancer.
